Note the following re our Phase 2 trial."The MagSense HER2...

Note the following re our Phase 2 trial.

"The MagSense HER2 imaging agent is our first and flagship program, where again, we’ve completed phase 1 and are out to find partnerships in the immediate future. Behind that, we have a very compelling program targeting ovarian cancer, which uses the folate molecule to drive binding to the folate receptor alpha."

That suggests to me, that they are looking to partnering the phase 2 trial on HER2 breast / other pipelines ?.

Any of which, IMO would change sentiment regarding the momentum of the trials ahead of us.